COMPOSITION
Flumeglin Injectable Solution is a sterile, colorless, and clear solution, each ml containing flunixin meglumine equivalent to 50 mg of flunixin base, 2.5 mg of sodium formaldehyde sulfoxylate as an antioxidant preservative and 5.0 mg of phenol as an antimicrobial preservative.
INDICATIONS FOR USE
Horse:
For the alleviation of inflammation and pain associated in musculo-skeletal disorders and for the alleviation of pain associated with colic
Cattle:
Used for the alleviation of clinical signs of respiratory disease when used concurrently with appropriate anti-infective therapy.
ADMINISTRATION ROUTES AND AMOUNTS
Intravenous administration should be performed slowly, and the product should be brought to body temperature before intravenous administration. Rapid intravenous injections are dangerous. Read other sections for further information.
Do not administer into an artery.
Horse:
Alleviation of inflammation and pain associated with musculo-skeletal disorders:
1 mg of flunixin per kg bodyweight, equivalent to 1 ml of solution per 50 kg bodyweight, administered once daily by intravenous injection for 1 to 5 consecutive days.
Alleviation of visceral pain associated with colic:
1 mg of flunixin per kg bodyweight, equivalent to 1 ml of solution per 50 kg bodyweight, administered once daily by intravenous injection. Treatment may be repeated once or twice if colic recurs.
Cattle:
2 mg of flunixin per kg bodyweight, equivalent to 2 ml of solution per 50 kg bodyweight, administered once daily by intravenous or intramuscular injection for 1 to 3 consecutive days. Volumes greater than 20 ml should be divided and administered at least at 2 different injection sites.
WITHDRAWAL PERIOD(S)
Cattle should not be sent for slaughter within 31 days for intramuscular application and 10 days for intravenous application during the treatment period and after the last drug administration. Withdrawal period for milk is 36 hours (3 milkings) for intramuscular application and 24 hours (2 milkings) for intravenous application after the last drug administration.
MARKETING PACKAGING
Sold as 50 ml, 100 ml, and 250 ml Type II amber glass vials, sealed with bromobutyl rubber stopper and a aluminum flip-off cap, packaged in a carton box.
